Vicore to Present at the Nordea Equities Healthcare Seminar

About this update from Vicore Pharma Holding Ab

[{"type":"text","content":"STOCKHOLM, SE / ACCESS Newswire / May 2, 2025 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced participation in the 2025 Nordea Equities Healthcare Seminar:","length":263,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Location: Stockholm, Sweden","length":27,"tagName":"p"}]},{"val":[{"type":"text","content":"Format: Presentation and 1x1 meetings","length":37,"tagName":"p"}]},{"val":[{"type":"text","content":"Presentation Date and Time: Thursday, May 8 at 11:25 AM CET","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Presenter: Hans Jeppsson, CFO","length":29,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":152,"olType":false},{"type":"text","content":"The company's management will also be available for meetings at the conference.","length":83,"tagName":"p"},{"type":"text","content":"For further information, please contact:Megan Richards, VP of IR, Communications, and Portfolio Strategy, tel: +1 978 269-4372, [email protected] Jeppsson, CFO, tel: +46 70 553 14 65, [email protected]","length":234,"tagName":"p"},{"type":"text","content":"About Vicore Pharma Vicore Pharma Holding AB is a clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid (C21), is a first-in-class oral small molecule angiotensin II type 2 (AT2) receptor agonist, which has received Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA) and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF.","length":595,"tagName":"p"},{"type":"text","content":"The company is publicly listed on the Nasdaq Stockholm exchange (VICO). www.vicorepharma.com","length":92,"tagName":"p"},{"type":"text","content":"AttachmentsVicore to Present at the Nordea Equities Healthcare Seminar","length":71,"tagName":"p"},{"type":"text","content":"SOURCE: Vicore Pharma Holding","length":29,"tagName":"p"},{"type":"text","content":"View the original press release on ACCESS Newswire","length":50,"tagName":"p"}]

More updates from Vicore Pharma Holding Ab